Payment overview · 2025
General Payments
$954.42
44 reported records · 9 companies
Healthcare provider profile · identity verified
Eden D Brandon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1063605814
Verified facts
What the public records show
CMS Open Payments records show Eden D Brandon, MD received $954.42 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $395.95 | 41.5% | 17 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $165.14 | 17.3% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.87 | 10.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.85 | 9.2% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $68.69 | 7.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.22 | 5.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.49 | 4.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.89 | 2.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.32 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $954.42 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $200.55 | 9 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $165.14 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $126.47 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $87.85 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.44 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $75.13 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.42 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $46.69 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $43.00 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.49 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 121 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
121 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 505 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 446 | 84 |
| Losartan Potassium | Losartan Potassium | 331 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 316 | 57 |
| Furosemide | Furosemide | 277 | 41 |
| Metformin Hcl | Metformin Hcl | 271 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 218 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 37 |
| Gabapentin | Gabapentin | 196 | 32 |
| Potassium Chloride | Potassium Chloride | 181 | 28 |
| Carvedilol | Carvedilol | 167 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 146 | 19 |
| Omeprazole | Omeprazole | 144 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 13 |
| Allopurinol | Allopurinol | 123 | 13 |
| Eliquis | Apixaban | 121 | 17 |
| Lisinopril | Lisinopril | 121 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 119 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 111 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 21 |
| Montelukast Sodium | Montelukast Sodium | 100 | 13 |
| Ezetimibe | Ezetimibe | 97 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 17 |
| Januvia | Sitagliptin Phosphate | 90 | 14 |
| Entresto | Sacubitril/Valsartan | 88 | suppressed |
| Glipizide | Glipizide | 87 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 12 |
| Spironolactone | Spironolactone | 86 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 14 |
| Nitroglycerin Patch | Nitroglycerin | 79 | suppressed |
| Mirtazapine | Mirtazapine | 77 | suppressed |
| Simvastatin | Simvastatin | 74 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 70 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 69 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 68 | 15 |
| Farxiga | Dapagliflozin Propanediol | 67 | suppressed |
| Nitroglycerin | Nitroglycerin | 66 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 65 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 65 | suppressed |
| Alprazolam | Alprazolam | 61 | suppressed |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 60 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | suppressed |
| Famotidine | Famotidine | 57 | suppressed |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | suppressed |
| Chlorthalidone | Chlorthalidone | 53 | 11 |
| Jardiance | Empagliflozin | 51 | suppressed |
| Ozempic | Semaglutide | 46 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Dulera | Mometasone/Formoterol | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Fluocinonide | Fluocinonide | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Desloratadine | Desloratadine | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 21 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Roflumilast | Roflumilast | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Clonidine | Clonidine | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $954.42 · 44 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAMZYOS, CAPVAXIVE, CARDIOMEMS, Cologuard Collection Kit, ELIQUIS, FARXIGA, GVOKE HYPOPEN, Kerendia, MOUNJARO, VERQUVO, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error